610 related articles for article (PubMed ID: 7502628)
21. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.
Little JA; McGowan VR; Kato GJ; Partovi KS; Feld JJ; Maric I; Martyr S; Taylor JG; Machado RF; Heller T; Castro O; Gladwin MT
Haematologica; 2006 Aug; 91(8):1076-83. PubMed ID: 16885048
[TBL] [Abstract][Full Text] [Related]
22. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
23. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea therapy in thalassemia.
Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N
Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534
[TBL] [Abstract][Full Text] [Related]
25. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
26. Hydroxyurea and sickle cell anemia: effect on quality of life.
Ballas SK; Barton FB; Waclawiw MA; Swerdlow P; Eckman JR; Pegelow CH; Koshy M; Barton BA; Bonds DR
Health Qual Life Outcomes; 2006 Aug; 4():59. PubMed ID: 16942629
[TBL] [Abstract][Full Text] [Related]
27. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
28. Long-term hydroxyurea therapy in beta-thalassaemia patients.
de Paula EV; Lima CS; Arruda VR; Alberto FL; Saad ST; Costa FF
Eur J Haematol; 2003 Mar; 70(3):151-5. PubMed ID: 12605659
[TBL] [Abstract][Full Text] [Related]
29. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
30. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
Maier-Redelsperger M; de Montalembert M; Flahault A; Neonato MG; Ducrocq R; Masson MP; Girot R; Elion J
Blood; 1998 Jun; 91(12):4472-9. PubMed ID: 9616141
[TBL] [Abstract][Full Text] [Related]
31. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study.
Nagel RL; Vichinsky E; Shah M; Johnson R; Spadacino E; Fabry ME; Mangahas L; Abel R; Stamatoyannopoulos G
Blood; 1993 Jan; 81(1):9-14. PubMed ID: 8417806
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
[TBL] [Abstract][Full Text] [Related]
33. Hydroxyurea for the treatment of sickle cell disease.
el-Hazmi MA; Warsy AS; al-Momen A; Harakati M
Acta Haematol; 1992; 88(4):170-4. PubMed ID: 1292305
[TBL] [Abstract][Full Text] [Related]
34. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
[No Abstract] [Full Text] [Related]
35. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
37. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
Papassotiriou I; Voskaridou E; Stamoulakatou A; Loukopoulos D
Hematol J; 2000; 1(5):295-300. PubMed ID: 11920206
[TBL] [Abstract][Full Text] [Related]
38. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
39. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
40. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
Ballas SK; Connes P;
Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]